Results 181 to 190 of about 125,121 (369)

Serum pepsinogen I/II ratio is correlated with albuminuria in patients with type 2 diabetes

open access: bronze, 2012
Takafumi Senmaru   +11 more
openalex   +2 more sources

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

Albuminuria and Mental Illness Risk: Results From National Health and Nutrition Examination Survey 2005–2018 and Mendelian Randomization Analyses

open access: yesBrain and Behavior
Background Recent evidence suggests a link between albuminuria and mental illness. However, whether this association is stable, and its specific mechanisms remain unclear.
Yangyang Wang, Sen Li
doaj   +1 more source

Enzyme-linked immunosorbent assay for urinary albumin at low concentrations [PDF]

open access: yes, 1987
We describe an enzyme-linked immunosorbent assay (ELISA) for urinary albumin. It requires only commercially available reagents, can detect as little as 16 micrograms of albumin per liter, and analytical recovery ranges from 92 to 116%.
Jesse, U.   +4 more
core  

Parity is associated with albuminuria and chronic kidney disease: a population-based study

open access: green, 2019
Kan Sun   +9 more
openalex   +2 more sources

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou   +5 more
wiley   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

open access: yesESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy